Zacks Research Weighs in on AngioDynamics FY2028 Earnings

AngioDynamics, Inc. (NASDAQ:ANGO) – Analysts at Zacks Research issued their FY2028 earnings estimates for AngioDynamics in a research report issued on Tuesday, August 5th. Zacks Research analyst R. Department expects that the medical instruments supplier will post earnings per share of ($0.04) for the year. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.37) per share.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.09. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. The business had revenue of $80.16 million for the quarter, compared to analyst estimates of $74.26 million. During the same quarter in the previous year, the firm posted ($0.06) earnings per share. AngioDynamics’s revenue was up 13.0% compared to the same quarter last year.

ANGO has been the topic of several other research reports. HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of AngioDynamics in a research note on Wednesday, July 16th. Canaccord Genuity Group upped their price target on shares of AngioDynamics from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Wednesday, July 16th. Finally, Lake Street Capital assumed coverage on shares of AngioDynamics in a research report on Wednesday, July 16th. They set a “buy” rating and a $24.00 price target on the stock.

AngioDynamics Price Performance

ANGO opened at $8.40 on Wednesday. AngioDynamics has a fifty-two week low of $5.83 and a fifty-two week high of $13.50. The firm’s fifty day moving average price is $9.70 and its two-hundred day moving average price is $9.86. The company has a market capitalization of $341.29 million, a P/E ratio of -10.12 and a beta of 0.67.

Institutional Trading of AngioDynamics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC bought a new stake in AngioDynamics during the 4th quarter worth about $387,000. Ameriprise Financial Inc. raised its holdings in AngioDynamics by 24.0% during the 4th quarter. Ameriprise Financial Inc. now owns 277,565 shares of the medical instruments supplier’s stock worth $2,542,000 after purchasing an additional 53,675 shares during the last quarter. GAMMA Investing LLC raised its holdings in AngioDynamics by 1,281.4% during the 1st quarter. GAMMA Investing LLC now owns 13,897 shares of the medical instruments supplier’s stock worth $130,000 after purchasing an additional 12,891 shares during the last quarter. GSA Capital Partners LLP bought a new stake in AngioDynamics during the 1st quarter worth about $642,000. Finally, New York State Common Retirement Fund raised its holdings in AngioDynamics by 667.0% during the 1st quarter. New York State Common Retirement Fund now owns 54,635 shares of the medical instruments supplier’s stock worth $513,000 after purchasing an additional 47,512 shares during the last quarter. 89.43% of the stock is owned by institutional investors.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.